AR074665A2 - Formula cristalina no solvatada de eplerenona (forma l), sustancia farmacologica y composicion farmaceutica que la comprenden - Google Patents
Formula cristalina no solvatada de eplerenona (forma l), sustancia farmacologica y composicion farmaceutica que la comprendenInfo
- Publication number
- AR074665A2 AR074665A2 ARP090104744A ARP090104744A AR074665A2 AR 074665 A2 AR074665 A2 AR 074665A2 AR P090104744 A ARP090104744 A AR P090104744A AR P090104744 A ARP090104744 A AR P090104744A AR 074665 A2 AR074665 A2 AR 074665A2
- Authority
- AR
- Argentina
- Prior art keywords
- eplerenone
- understand
- pharmaceutical composition
- prepare
- crystalline
- Prior art date
Links
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title abstract 10
- 229960001208 eplerenone Drugs 0.000 title abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- QBIRIYASLUPKQB-CBHLJOAQSA-N epierenone Chemical compound C1([C@]2(C)[C@H]3O[C@H]3C3[C@@]4(C)CCC(=O)C=C4C[C@H](C13)C(=O)OC)CC[C@@]21CCC(=O)O1 QBIRIYASLUPKQB-CBHLJOAQSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16970799P | 1999-12-08 | 1999-12-08 | |
| US16968399P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US16980799P | 1999-12-08 | 1999-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074665A2 true AR074665A2 (es) | 2011-02-02 |
Family
ID=27558586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104744A AR074665A2 (es) | 1999-12-08 | 2009-12-07 | Formula cristalina no solvatada de eplerenona (forma l), sustancia farmacologica y composicion farmaceutica que la comprenden |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090149431A1 (enExample) |
| EP (1) | EP1175434A2 (enExample) |
| JP (2) | JP4219105B2 (enExample) |
| KR (1) | KR100584104B1 (enExample) |
| CN (1) | CN100413881C (enExample) |
| AR (1) | AR074665A2 (enExample) |
| AU (1) | AU2041101A (enExample) |
| BR (1) | BR0008054A (enExample) |
| CA (1) | CA2362845A1 (enExample) |
| CO (1) | CO5280205A1 (enExample) |
| EA (1) | EA008449B1 (enExample) |
| HU (1) | HUP0201457A3 (enExample) |
| IL (2) | IL144757A0 (enExample) |
| MY (1) | MY143571A (enExample) |
| NO (1) | NO20013857L (enExample) |
| NZ (1) | NZ513962A (enExample) |
| PE (1) | PE20010918A1 (enExample) |
| WO (1) | WO2001041535A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010821A1 (it) * | 2001-04-17 | 2002-10-17 | Gienne Pharma S P A | Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| CN104844681B (zh) * | 2014-02-13 | 2016-06-01 | 合肥久诺医药科技有限公司 | 一种l晶型依普利酮的精制方法 |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| CN108059648A (zh) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | 一种依普利酮溶剂合物及其制备方法 |
| CN113173968B (zh) * | 2021-03-19 | 2026-05-29 | 江苏苏中药业研究院有限公司 | 一种依普利酮的纯化方法 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) * | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| WO1997021720A2 (en) * | 1995-12-11 | 1997-06-19 | G.D. Searle And Co. | Processes for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olifinic double bonds |
| NZ336004A (en) * | 1996-12-11 | 2001-04-27 | G | Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base |
| JP2002538172A (ja) * | 1999-03-05 | 2002-11-12 | ジー．ディー．サール エルエルシー | 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法 |
-
2000
- 2000-12-04 AU AU20411/01A patent/AU2041101A/en not_active Abandoned
- 2000-12-04 CN CNB008057710A patent/CN100413881C/zh not_active Expired - Fee Related
- 2000-12-04 NZ NZ513962A patent/NZ513962A/en not_active IP Right Cessation
- 2000-12-04 HU HU0201457A patent/HUP0201457A3/hu unknown
- 2000-12-04 KR KR1020017010042A patent/KR100584104B1/ko not_active Expired - Fee Related
- 2000-12-04 JP JP2001542722A patent/JP4219105B2/ja not_active Expired - Fee Related
- 2000-12-04 EA EA200100869A patent/EA008449B1/ru not_active IP Right Cessation
- 2000-12-04 EP EP00983683A patent/EP1175434A2/en not_active Withdrawn
- 2000-12-04 BR BR0008054-3A patent/BR0008054A/pt not_active Application Discontinuation
- 2000-12-04 WO PCT/US2000/030178 patent/WO2001041535A2/en not_active Ceased
- 2000-12-04 CA CA002362845A patent/CA2362845A1/en not_active Abandoned
- 2000-12-04 IL IL14475700A patent/IL144757A0/xx active IP Right Grant
- 2000-12-06 CO CO00093237A patent/CO5280205A1/es not_active Application Discontinuation
- 2000-12-06 MY MYPI20005735A patent/MY143571A/en unknown
- 2000-12-06 PE PE2000001302A patent/PE20010918A1/es not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144757A patent/IL144757A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013857A patent/NO20013857L/no not_active Application Discontinuation
-
2006
- 2006-09-04 JP JP2006238694A patent/JP2007016043A/ja active Pending
-
2009
- 2009-02-18 US US12/388,228 patent/US20090149431A1/en not_active Abandoned
- 2009-12-07 AR ARP090104744A patent/AR074665A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20013857D0 (no) | 2001-08-08 |
| EP1175434A2 (en) | 2002-01-30 |
| HUP0201457A3 (en) | 2003-07-28 |
| EA008449B1 (ru) | 2007-06-29 |
| JP4219105B2 (ja) | 2009-02-04 |
| JP2003515611A (ja) | 2003-05-07 |
| NO20013857L (no) | 2001-10-08 |
| WO2001041535A9 (en) | 2002-07-04 |
| WO2001041535A2 (en) | 2001-06-14 |
| JP2007016043A (ja) | 2007-01-25 |
| KR100584104B1 (ko) | 2006-05-30 |
| BR0008054A (pt) | 2002-03-12 |
| NZ513962A (en) | 2004-08-27 |
| CN1433427A (zh) | 2003-07-30 |
| CA2362845A1 (en) | 2001-06-14 |
| AU2041101A (en) | 2001-06-18 |
| PE20010918A1 (es) | 2001-09-10 |
| HUP0201457A2 (en) | 2002-08-28 |
| US20090149431A1 (en) | 2009-06-11 |
| HK1057220A1 (zh) | 2004-03-19 |
| CO5280205A1 (es) | 2003-05-30 |
| CN100413881C (zh) | 2008-08-27 |
| KR20020003192A (ko) | 2002-01-10 |
| IL144757A0 (en) | 2002-06-30 |
| EA200100869A1 (ru) | 2002-04-25 |
| WO2001041535A3 (en) | 2001-11-22 |
| MY143571A (en) | 2011-05-31 |
| IL144757A (en) | 2007-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200375926A1 (en) | Injectable resiniferatoxin | |
| Hsieh et al. | Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine | |
| IL320522A (en) | Crystalline forms of an androgen receptor modulator | |
| PE20070492A1 (es) | Forma cristalina delta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
| BRPI0713565B8 (pt) | processo para fabricação de uma forma de dosagem oral sólida | |
| CO6160317A2 (es) | Formas de dosificacion farmaceutica no manipulables que incluyen un analgesico opioide | |
| Major et al. | A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine | |
| Hersh et al. | Dose-ranging analgesic study of prosorb® diclofenac potassium in postsurgical dental pain | |
| WO2020094698A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| Cuppoletti et al. | Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors | |
| JP2023110041A (ja) | ホットフラッシュの新規処置法 | |
| AR025779A1 (es) | Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion. | |
| BR0008054A (pt) | Forma cristalina de eplerenona | |
| BR0008057A (pt) | Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada | |
| ES2829578T3 (es) | Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona | |
| KR20120099215A (ko) | 다운 증후군을 치료하기 위한 방법 및 약학적 조성물 | |
| KR100674053B1 (ko) | 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도 | |
| EP4009977A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| BRPI0408805A (pt) | composição farmacêutica contendo complexo de platina e método de fabricação da mesma | |
| ES2693156T3 (es) | Comprimido de liberación sostenida que contiene levodropropizina y método para prepararlo | |
| AR033965A1 (es) | Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas | |
| WO2020160379A1 (en) | Polymeric implants with high drug loading and long-acting drug release and methods of making the same | |
| WO2020247485A1 (en) | Modified peptides and associated methods of use | |
| AR026747A1 (es) | Forma cristalina de eperenona | |
| CO5271647A1 (es) | Metodo para prevenir la diarrea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |